Figure 1.

Reactivity of different sera against recombinant ribosomal P proteins and corresponding C-terminal peptides measured by ELISA. Sera from patients with cChHD (n = 15), SLE (n = 6), leishmaniasis (Leish, n = 4), and idiopathic dilated cardiomyopathy (IDC, n = 4) were tested against (A) recombinant proteins derived from T. cruzi (TcP1 and TcP2β) and human (HuP1 and HuP2) ribosomal P proteins, and (B) peptides R13, R11, H13, H11, C10, and C7. Sera were used at a 1:400 dilution. Mean plus standard deviations are shown. ∗, Significant differences (P < 0.01) were observed between antibody levels against TcP1 and TcP2β when compared with anti-HuP2 antibody levels and between anti-R13 and -R11 levels when compared with anti-H13 antibody levels. Arrows indicate the cut-off lines defined as the mean ± 2 SD of the OD₄₁₅ values obtained from 10 healthy donors.